Sandoz announced today that is has received approval from the European Commission for its biosimilar etanercept (which will be marketed as Erelzi) for the treatment of multiple inflammatory diseases, including rheumatoid arthritis, axial spondyloarthritis, psoriasis, and psoriatic arthritis.
Sandoz announced today that is has received approval from the European Commission for its biosimilar etanercept (which will be marketed as Erelzi) for the treatment of multiple inflammatory diseases, including rheumatoid arthritis, axial spondyloarthritis, psoriasis, and psoriatic arthritis.
The European Commission based its approval on analytical, preclinical, and clinical data that demonstrated biosimilarity of Sandoz’s product to the reference etanercept (Amgen’s Enbrel). Clinical trials included a pharmacokinetic (PK) study that demonstrated bioequivalence of the 2 treatments, and that did not reveal any clinically relevant differences in safety, tolerability, or immunogenicity between the biosimilar and its reference. The product’s phase 3 study, which included 3 treatment switches between the biosimilar and the reference product, met its primary endpoint of achieving an equivalent PASI 75 response rate (a 75% reduction in the psoriasis area and severity index) by week 12 of treatment, and generated confirmatory efficacy, safety, and immunogenicity data.
“Immunology is a priority for us and today’s approval of Erelzi, the second in this therapy area in as many weeks, clearly demonstrates our commitment to patients. This can also be seen in the progress we are making in our immunology pipeline with 2 recent file acceptances in Europe,” said Carol Lynch, global head of biopharmaceuticals at Sandoz.
Erelzi marks Sandoz’s 5th biosimilar approval in Europe, but the drug manufacturer faces challenges in bringing the treatment to the US marketplace. Last week, a Nobel Prize-winning researcher, Bruce Beutler, MD, of the University of Texas Southwestern Medical Center, moved to block a Sandoz subpoena seeking his testimony in patent litigation over Erelzi. Sandoz, in its ongoing fight to invalidate 2 of 5 patents asserted by Amgen for its innovator etanercept, sought to compel Dr Beutler’s testimony concerning a 1995 patent for his work on tumor necrosis factor inhibitors.
Counsel for Dr Beutler asked the court, as an alternative to quashing the subpoena, to issue a protective order that would shield him from having to offer his expert opinion about the similarity of the reference and biosimilar molecules.
While Sandoz gained FDA approval for its product in 2016, such ongoing litigation will continue to delay US patient access to the biosimilar treatment; earlier this year, Richard Francis, division head of Sandoz for Novartis, told Reuters that he expected legal delays to extend until 2018. "That's the frustration sometimes of the legal situation,” Francis said, “but the way I look at that, we're carving the landscape out as we go."
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.